A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 21 - 75 |
| Updated: | 4/21/2016 |
| Start Date: | April 2014 |
| End Date: | September 2016 |
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Obese Adults With Type-2 Diabetes
The purpose of this study is to assess the potential of BMS-986036 for treatment obese
adults with type-2 diabetes.
adults with type-2 diabetes.
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com
Inclusion Criteria:
- Diagnosed with type-2 diabetes mellitus with HbA1c ≥6.5% to less than 10.0%
- Body mass index 30.0 to 50.0
Exclusion Criteria:
- Any significant acute or chronic medical illness
- Inability to self-administer subcutaneous injections
- Inability to be venipunctured
- Evidence of organ dysfunction beyond what is consistent with the target population
- History of allergy to PEGylated compounds or Fibroblast growth factor 21 (FGF21)
related compounds
We found this trial at
10
sites
Click here to add this to my saved trials
Anaheim Clinical Trials, LLC Anaheim Clinical Trials (ACT) is a research center of excellence for...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials